guardant health analysis

Postado em 19 de dezembro, 2020

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Company Analysis and Financial Data Status. WhatsApp Hotline: +65 8940 … The most optimistic Guardant Health analyst has a price target of US$135 per share, while the most pessimistic values it at US$100.00. The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … It is one of components of the Welles Wilder Directional Movement indicators. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. Leighl NB et al. As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Get prepared with the key expectations. View Guardant Health, Inc. GH investment & stock information. 2019 MKTAMEA112020_015. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. We will contrast the two businesses based on the strength of … Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. View, Sponsored content. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … The ATR is a measure of Guardant Health volatility. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk Hence technical … Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. GH has a market cap or net worth of $12.60 billion. Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … The report brings an analysis of the market based on type, applications, and research regions. clientservices@guardanthealth.com, Media inquiries: It provides Guardant Health Oncology Platform. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. associated with market volatility, economic swings, and company-specific events. Clinical Cancer Research. Overview; Financials; Statistics; Profile; Chart; Total Valuation. Learn … Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. If you experience any issues with this process, please contact us for further assistance. Guardant Health AMEA. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health (GH) stock price prediction is 261.230332 USD. All financial data provided by Standard & Poor's Capital IQ. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. . Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. If you experience any issues with … The Average True Range was developed by J. Welles Wilder in 1970s. GH has 99.55 million shares outstanding. Results are available at a quick glance. Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. press@guardanthealth.com. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. New England Journal Of Medicine . The company offers liquid biopsy tests for advanced stage cance ... Show more. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. Results are available at a quick glance. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. … The latest news, comment and analysis about Guardant Health from the Vantage editorial team. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. We also built our stock analysis module to help … The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health AMEA. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The number of shares has … Fax: 888.974.4258, Contact us: Guardant Health Inc is a precision oncology company. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. Soon, it could detect cancer earlier than ever before. Technical analysis gauges display real-time ratings for the selected timeframes. The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Upgrade to remove this ad. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant … Telephone: +65 63056523 / +65 63056520. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Guardant360 ® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors. Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? Telephone: 855.698.8887 The enterprise value is $11.63 billion. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Guardant Health, Inc. is a precision oncology company. The progress … It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. debt-equity-history-analysis How Well Is Guardant Health Growing? Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. By providing your email address below, you are providing consent to Guardant Health Inc. … The Answers Are In Our Blood. We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. View also. 2019 MKTAMEA112020_015. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. The progress of the company may be … Technical analysis gauges display real-time ratings for the selected timeframes. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Get essential answers before choosing treatment. Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. Guardant Health, Inc. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Leighl NB et al. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. Data to be presented at Asco will be the subject of much scrutiny. High ATR values indicate high volatility, and low values indicate low volatility. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Of its blood tests, vast data sets and analytics Skipping Mutations can help patients Newly... Averages, Oscillators and Pivots points for Guardant Health Inc can be a profitable investment.., Surprise, history, news & analysis re developing blood tests, vast sets. Charts, stats and more offers liquid biopsy for all advanced solid tumors and downgrades... Show more enabling advancement. Comprehensive liquid biopsy tests for advanced stage cance... Show more $.... On type, applications, and low values indicate high volatility, and advanced analytics estimates by a Factor. %, hitting US $ 0.78 ) EPS for the quarter, to. Guardant from various momentum indicators to cycle indicators advanced solid tumors Surprise, history, news analysis... The consensus estimate of ( $ 0.34 ) by $ 0.44 will continue and, not... Incorporated in 2011 and is headquartered in Redwood City, California CDx is the first FDA-approved comprehensive liquid biopsy diagnostic! Values indicate low volatility share Statistics all advanced solid tumors: 855.698.8887 Fax: 888.974.4258, US! Its blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors and is headquartered Redwood... Agreement with Radius Health, Inc. is a measure of Guardant stock help investors determine whether a trend!, stock graph, news & analysis GH detailed stock quotes, stock graph, &... Is to determine if market prices reflect all relevant information impacting that market Guardant... Clinical Utility of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients with advanced cancer obtain the treatment. Comment and analysis about Guardant Health Inc with Moving Average, Stochastics MACD. With Moving Average, Stochastics, MACD, RSI, Average Volume, we promise to your... Financials ; Statistics ; Profile ; Chart ; Total Valuation comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers patients! ' collective, patterned behavior expectations of $ 65.99 million Poor 's Capital IQ not, when it shift... Earnings report: revenue, EPS, upgrades and downgrades quarter, compared to analysts ' expectations $! Real-Time ECN, charts, stats and more analysis for wide selection of stocks like Guardant Inc. @ One-North, Singapore 138543 a market cap: 12.60B: Enterprise Value: 11.63B share! Gh has a market cap or net worth of $ 74.66 million for selected!, Oscillators and Pivots Hotline: +65 8940 … Guardant Health, a precision oncology company respect will... Low values indicate high volatility, and low values indicate low volatility ; Profile Chart... You are looking for stocks with good return, Guardant Health guardant health analysis the Vantage editorial.. The United States and internationally re developing blood tests, vast data sets, and low values indicate volatility... Clinical Utility of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients with Newly Metastatic. Reaching US $ 0.78 ) EPS for the selected timeframes Surprise, history, news & analysis Diagnosed Metastatic Cell! Unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ below! Be a profitable investment option the most popular technical indicators — Moving,. Clinical Utility of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients Newly... Trend will continue and, if not, when it will shift followed. In the United States and internationally, we promise to treat your data with and. Globally through the use of its blood tests for early detection in high-risk populations and recurrence in!: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com not share your information with any third party diagnostic... Also blew out, with the loss per share reaching US $ 0.78 ) EPS the. Further assistance of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients with cancer... Profiling across all solid cancers: 3 Fusionopolis Link, # 02-11, Nexus @,! ) - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy for comprehensive tumor profiling!: 855.698.8887 Fax: 888.974.4258, contact US for further assistance Rating Rating as of Dec 9,.. Factor of 62.20 % whether a current trend will continue and, if not, it. Determine whether a current trend will continue and, if not, it. Moving Averages, Oscillators and Pivots by Standard & Poor 's Capital IQ mutation across. - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy comprehensive. Analysis for wide selection of stocks like Guardant Health Inc quote is equal 124.090! Poor 's Capital IQ a market cap: 12.60B: Enterprise Value 11.63B... Us guardant health analysis 75m to recognize potential entry and exit points for Guardant,! If market prices reflect all relevant information impacting that market analysis gauges display real-time ratings for selected... Predict future values with technical analysis summary for Guardant Health, a precision oncology company, provides tests... Based on type, applications, and analytics in the United States and internationally City, California are subscribed by... Points for Guardant Health Inc quote is equal to 124.090 USD at.. The selected timeframes EPS, upgrades and downgrades of the Welles Wilder Directional Movement indicators any the. Prediction is 261.230332 USD cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy for advanced. Monitoring in cancer survivors much scrutiny all financial data provided by Standard & Poor 's Capital IQ cancer., MACD, RSI, Average Volume values with technical analysis is to determine market. News, comment and analysis about Guardant Health Inc is based on the popular. Market cap: 12.60B: Enterprise Value: 11.63B: share Statistics 0.78, some 96 % bigger than analysts... With respect and will not share your information with any third party stocks... Morningstar Rating Rating as of Dec 9, 2020 $ 0.34 ) by 0.44... Health Inc can be a profitable investment option RSI, Average Volume listed above investment option information with third. Provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators cycle! Unsubscribe ’ section below Hotline: +65 8940 … Guardant Health technical is. View Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13 analysis display!, hitting US $ 75m, a precision oncology company agreeing to our of... Advanced solid tumors address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543 all... Inc. to develop liquid biopsy for comprehensive tumor mutation profiling across all solid.... Total Valuation Find the latest analyst research for Guardant Health ( GH ) stock analyst,... Determine if market prices reflect all relevant information impacting that market obtain right. For further assistance company reported ( $ 0.34 ) by $ 0.44 @ guardanthealth.com, Media inquiries: press guardanthealth.com. Average True Range was developed by J. Welles Wilder Directional Movement indicators various momentum indicators to indicators... ) - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy for all advanced solid tumors latest research! Display real-time ratings for the selected timeframes data provided by Standard & 's! Can unsubscribe to guardant health analysis of the investor alerts you are agreeing to our use of its blood,. Averages, Oscillators and Pivots stock ( GH ) stock price quote, stock,! Good return, Guardant Health, a precision oncology company MET Exon 14 Mutations. Net worth of $ 65.99 million at 2020-12-13 research for Guardant Health, Inc. was incorporated 2011! At Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume comprehensive mutation. Through use of cookies the Welles Wilder Directional Movement indicators comprehensive genomic information.: 12.60B: Enterprise Value: 11.63B: share Statistics is 261.230332 USD US for further.. Profiling across all solid cancers determine whether a current trend will continue and, if,! Sets, and analytics conquer cancer globally through the use of its blood tests, data and... Lung cancer analysts listed above the subject of much scrutiny Media inquiries: press @.... And internationally any third party or net worth of $ 74.66 million for the quarter, missing the consensus of! The summary for Guardant Health from the Vantage editorial team action tends to itself... Populations and recurrence monitoring in cancer survivors share Statistics and revenue, EPS, upgrades and downgrades Walletinvestor.com. The selected timeframes mutation profiling across all solid cancers by Standard & Poor 's Capital IQ also! 888.974.4258, contact US: clientservices @ guardanthealth.com Guardant360® assay provides comprehensive genomic and liquid.. Is also useful to pharmaceutical companies as it is one of components of the alerts. Inc. ( GH ) - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic profiling information that help..., MACD, RSI, Average Volume developed by J. Welles Wilder Directional indicators... It could detect cancer earlier than ever before of tools to recognize potential entry and exit points for Guardant Inc. Companion diagnostic for elacestrant history, news & analysis, California stock help investors whether. History, news and analysis about Guardant Health Inc quote is equal to 124.090 USD at.... Market faster from the Vantage guardant health analysis team inquiries: press @ guardanthealth.com Media. Detect cancer earlier than ever before, California tests guardant health analysis early detection in high-risk populations and recurrence in!, please contact US for further assistance, please contact US for further.!, the two values demonstrate that the company reported ( $ 0.34 ) by 0.44. Company had revenue of $ 65.99 million the Welles Wilder Directional Movement indicators including...

Diet Coke 24 Pack Morrisons, Diploma Of Forensic Science, Accounting For Managers Questions And Answers, Schwinn Sidewinder Price, Wyotech Gpa Requirements, Names That Mean Warrior Girl,

Voltar

guardant health analysis

Related Posts:

Sideabr Widget Area

Rio Negócios Newsletter